A small molecule inhibitor of CCR2 (CCR2-CCL2 signaling axis), PF-04136309, was tested in a phase 1 trial (NCT01413022) in combination with FOLFIRINOX (combination of oxaliplatin, irinotecan, leucovorin, and fluorouracil) in patients with borderline resectable and locally advanced pancreatic adenocarcinoma. This evidence concerns the gene CCR2 and pancreatic adenocarcinoma.